Federated Hermes Inc. Acquires 26,887 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Federated Hermes Inc. raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 130,688 shares of the biopharmaceutical company's stock after buying an additional 26,887 shares during the quarter. Federated Hermes Inc. owned about 0.08% of TG Therapeutics worth $3,934,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its holdings in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the last quarter. Blue Trust Inc. increased its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares during the period. Brookstone Capital Management grew its holdings in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 624 shares during the period. Daymark Wealth Partners LLC raised its holdings in shares of TG Therapeutics by 1.7% in the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after purchasing an additional 689 shares in the last quarter. Finally, New York State Teachers Retirement System increased its holdings in shares of TG Therapeutics by 1.9% in the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after buying an additional 837 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

Remove Ads

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded up $0.62 during trading hours on Tuesday, hitting $39.03. 1,600,072 shares of the stock were exchanged, compared to its average volume of 3,110,681. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.32. The company's 50 day moving average is $35.98 and its 200 day moving average is $31.60. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $6.13 billion, a P/E ratio of -390.26 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of a number of analyst reports. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.